a cure for hep c, aids, the flu and dengue..., page-135

G'day Moonwalker,

As Chuck said, they are indeed one and the same, which presents us with quite interesting investment situation. If BIT225 can satisfy the safety outcomes of this trial, then even if there is inadequate reduction in HCV load now, there is still the enormous upside of the HIV trial. The drug's interaction with the p7 in HCV in no way precludes action against the Vpu protein in HIV.

Essentially, we (the shareholders) are getting two safety trials for the price of one. This trial will potentially demonstrate that the human body can tolerate a certain amount of BIT225 (400mg x 2 dose per day x 28 days). Even if the drug is ineffective in killing HCV, the company will be able to move forward with the HIV trial as it exploits a different mode of action.

As you are no doubt aware, some patients have already successfully completed the full dosing phase. It would be improper for the company to make an announcement to this effect, however, I feel that we as shareholders can infer a significant reduction in risk.

There's a lot of upside here provided one considers the critical importance of the safety outcomes.